Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Reck et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d962b77fca1f84ab684ea9 — DOI: https://doi.org/10.1200/jco.18.00149

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer· 2018 · 3,620 citations
2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer· 2018 · 6,552 citations
3. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer· 2016 · 351 citations
4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,244 citations
5. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.· 2018 · 192 citations